One To Watch

Oruka Therapeutics

Company Overview

A clinical-stage biotechnology company engineering extended half-life monoclonal antibodies targeting validated immunological pathways to redefine the standard of care for plaque psoriasis, psoriatic arthritis, and related dermatologic indications. Oruka applies state-of-the-art antibody engineering to well-characterized modes of action, seeking to improve both efficacy and dosing convenience beyond what current biologics offer. The company's name reflects its mission — derived from or (Hebrew for "skin") and arukah ("restoration"). Oruka trades on Nasdaq under the ticker ORKA.

Headquarters and Global Presence

Oruka Therapeutics is headquartered in Menlo Park, California, and currently employs approximately 28 full-time staff. The company operates as a focused clinical-stage organization, with its activities concentrated in the United States.

Founding and History

Oruka was established as a privately held biotechnology company with backing from Paragon Therapeutics, a biologics discovery engine known for advancing best-in-class antibody programs. The company entered the public markets through a reverse merger with ARCA biopharma, announced in early 2024, which provided Oruka with a Nasdaq listing and capital to advance its pipeline. The transaction was structured to position Oruka as a publicly traded clinical-stage dermatology company under the ORKA ticker. The merger represented a clean strategic pivot, with the combined entity dedicated exclusively to Oruka's chronic skin disease programs.

Therapy Areas and Focus

Oruka's primary focus is moderate-to-severe plaque psoriasis, one of the most prevalent chronic immune-mediated skin diseases, affecting tens of millions of patients globally. The company is also developing programs for psoriatic arthritis and other inflammatory and dermatologic indications. Despite meaningful advances with IL-17 and IL-23 inhibitors, a significant proportion of patients fail to achieve or maintain deep, durable responses — representing the unmet need Oruka targets. The company's strategic thesis is that engineered half-life extension can translate validated biology into a step-change improvement in clinical outcomes and patient experience.

Technology Platforms and Modalities

Oruka's platform centers on half-life extended monoclonal antibody engineering, applying modifications to the Fc region of antibodies to substantially prolong systemic exposure. This approach aims to enable less frequent dosing — potentially quarterly or longer — while maintaining or exceeding the efficacy levels seen with current approved biologics. The company focuses on targets already clinically validated in psoriasis, such as the IL-23p19 subunit, reducing the mechanistic risk inherent in first-in-class programs. Leveraging Paragon Therapeutics' discovery capabilities, Oruka has access to a robust antibody optimization engine to support pipeline expansion beyond its lead asset.

Key Pipeline and Programs

ORKA-001 is Oruka's lead asset — a novel half-life extended IL-23p19 monoclonal antibody designed for the treatment of moderate-to-severe plaque psoriasis. IL-23p19 inhibition is one of the most clinically validated mechanisms in dermatology, with approved agents including risankizumab and guselkumab demonstrating high PASI response rates. ORKA-001 is engineered to extend dosing intervals significantly beyond those of existing IL-23 inhibitors, targeting a potential once-quarterly or less frequent regimen. The asset is currently in the EVERLAST-A Phase IIa trial, evaluating efficacy and safety in patients with moderate-to-severe plaque psoriasis. Positive interim data at week 16 were reported in April 2026, demonstrating compelling early efficacy signals that drove substantial investor confidence. Beyond ORKA-001, Oruka has indicated plans to expand its pipeline into psoriatic arthritis and additional inflammatory indications, leveraging the same half-life extension platform.

Recent Developments

In April 2026, Oruka reported positive interim week 16 data from the EVERLAST-A Phase IIa trial of ORKA-001 in moderate-to-severe plaque psoriasis, sending shares up nearly 26% to $85.67 in pre-market trading on April 27. The data readout represents the most significant clinical milestone in the company's history as a public entity and establishes proof-of-concept for the half-life extended IL-23p19 approach. Full Phase IIa data from EVERLAST-A are expected to guide the design and timing of a potential Phase III program.

Key Personnel

The leadership team at Oruka comprises seasoned biopharma executives with deep experience in immunology and biologics development. Jacob Sands serves as Chief Executive Officer, bringing extensive drug development and company-building experience from prior roles in clinical-stage biotech. The executive team is supported by scientific and clinical leadership drawn from organizations with track records in dermatology and inflammatory disease drug development, reflecting Oruka's commitment to execution across both discovery and clinical operations.

Strategic Partnerships

Oruka's foundational relationship with Paragon Therapeutics underpins its antibody discovery and engineering capabilities, providing access to a platform that has identified and optimized the company's lead programs. The reverse merger with ARCA biopharma in 2024 provided Oruka with public market access and an established corporate infrastructure. The company continues to evaluate partnership opportunities to support pipeline expansion into psoriatic arthritis and additional indications.

FAQ Section

Oruka's strategy is to take mechanistically validated IL-23 inhibition — already proven by risankizumab and guselkumab — and engineer substantially extended half-lives to enable less frequent dosing. The hypothesis is that a well-tolerated quarterly or longer dosing schedule could meaningfully differentiate from existing approved agents on patient convenience and adherence without sacrificing efficacy. This approach reduces target risk while competing on a clinically meaningful axis.

IL-23 drives the differentiation and maintenance of Th17 cells, which produce IL-17 — the downstream cytokine central to psoriatic skin inflammation. Selectively blocking the p19 subunit of IL-23 interrupts this pathogenic cascade while sparing IL-12, which plays a role in immune surveillance. Clinical validation is well established, with IL-23p19 inhibitors consistently achieving PASI 90 and PASI 100 response rates that were historically unattainable, making the target highly credible for next-generation engineering efforts.

Approved IL-23p19 inhibitors such as risankizumab require subcutaneous injections every 12 weeks after induction. ORKA-001 uses Fc-region engineering to substantially prolong systemic exposure, targeting dosing intervals of quarterly or potentially longer. If the Phase IIa data translate into Phase III and regulatory approval, this could represent a meaningful quality-of-life improvement and a differentiated commercial position, particularly for patients seeking minimal treatment burden.

Interim week 16 data from the EVERLAST-A Phase IIa trial, reported on April 27, 2026, were characterized by Oruka as positive in patients with moderate-to-severe plaque psoriasis. The readout triggered a nearly 26% surge in the company's share price to $85.67 in pre-market trading, reflecting strong investor confidence in the early efficacy signal. Full Phase IIa results will be key to determining the dose and dosing interval to advance into a potential Phase III program.

While plaque psoriasis is the initial and primary focus, Oruka has explicitly identified psoriatic arthritis as a second key indication, reflecting the significant overlap in pathophysiology between the two diseases. The company also references broader dermatologic and inflammatory indications as longer-term targets, suggesting an ambition to expand the half-life extension platform across multiple immune-mediated conditions. This pipeline logic mirrors the expansion trajectories of IL-17 and IL-23 class competitors, which built large franchises across skin and joint diseases.

Oruka is a clinical-stage company with its lead asset ORKA-001 currently in Phase IIa development. The positive week 16 interim data from EVERLAST-A, reported April 2026, represent the company's first major clinical proof-of-concept as a public entity. The next critical milestone is full Phase IIa data from EVERLAST-A, which will inform Phase III trial design, including the dosing regimen and patient population, and will likely be the most significant near-term value-creation event for the company.

Oruka is at an inflection point following its first positive clinical readout. Key watchpoints include:

Full EVERLAST-A Phase IIa data: the complete dataset will test whether week 16 signals hold and validate the extended dosing hypothesis.
Phase III design and initiation: the transition from Phase IIa to a registrational trial is a major execution and capital milestone.
Competition: risankizumab, guselkumab, and pipeline long-acting biologics from larger companies represent ongoing commercial and clinical competition.
Cash runway: as a small-cap clinical-stage company with approximately 28 employees, Oruka's ability to fund Phase III without dilutive financing will be closely watched.
Pipeline expansion: progress toward psoriatic arthritis or additional indications would broaden the investment thesis beyond a single-asset story.

Want to Update your Company's Profile?